TECHNOLOGY
A Drug Delivery System (DDS) based on novel platform technology, Laminar-FLUIDigmTM, for the development of innovative drugs.
Laminar-FLUIDigm™
Process engineering technology for
microfluidic-based pharmaceutical drugs manufacturing
Microfluidic system had been previously applied to chemical processes and
diagnostic devices, however, there had been hardly any cases of such application in
DDS due to the difficulties in the direct applications of microfluidics to drug
formulation and manufacturing.
With our fully in-house developed process module, we are able to apply microfluidics
directly to the formulation and manufacturing of pharmaceutical drugs.
IVL-DrugFluidic®
A platform technology of Laminar-FLUIDigm™
applied to microsphere-based long acting injectables
formulation and mass production.
IVL-DrugFluidic® is a Micro-Electro Mechanical Systems (BIO-MEMS)
technology based on microfluidics, an innovative microsphere manufacturing
technology that integrates hydrodynamics to pharmaceutical manufacturing
technology using microchannels as a basic unit.
The ability to freely adjust the particle properties, such as particle size;
distribution; and porosity during manufacturing process serves as a major
advantage of the system, allowing high yield and adjustable batch sizes.
Unlike other biopharmaceutical companies, we have an internal team of
experts overseeing our entire platform technology, from process design and
optimization to the building of equipment itself. This allows us to secure a
distinct position in the industry.
IVL-GeneFluidic®
A platform technology of Laminar-FLUIDigm™
applied to lipid nanoparticles, the delivery carrier for mRNA
vaccines, for its formulation and manufacturing process.
mRNA, the key substance of the vaccine, is easily degraded when
administered to the human body. Hence, it requires safe and stable delivery
systems.
When lipid particles and mRNAs flow down a small flow path of several
hundred micrometers (μm), these lipids surround the mRNA and create a
spherical LNP structure.
Inventage Lab has achieved the technology excellence to create such LNP
structure to encapsulate 95 - 98% of mRNA with our own microfluidic-based
technology for mass production.
